Inside the vVARDIS Holding AG IPO: Growth, Risks, and Verdict
vVARDIS Holding AG Class A is expected to list on the NYSE on 2026-11-13 in a priced IPO at $21.00 to $24.00 per share. The Swiss oral-health company is coming public with rapid revenue growth, but it is still loss-making and heavily dependent on U.S. adoption of its core product.
vVARDIS Holding AG Class A is expected to list on the NYSE on 2026-11-13 in a priced IPO at $21.00 to $24.00 per share. The Swiss oral-health company is coming public with rapid revenue growth, but it is still loss-making and heavily dependent on U.S. adoption of its core product.
Quick Facts
Expected listing date: November 13, 2026
Exchange: NYSE
Proposed symbol: VVVV
Price range: 21.00 - 24.00
Shares offered: 8.33M shares
Implied market cap: $291M
Status: Priced
Company Overview
vVARDIS is a Swiss dental med-tech company headquartered in Zug, Switzerland, with its registered office at Gubelstrasse 24, 6300 Zug. The company says it primarily derives revenue from customers in the United States and was founded in 2020 by Dr. Haley Abivardi and Dr. Goly Abivardi, both dentists and serial entrepreneurs.
Its core platform is Curodont, a family of products aimed at early-stage cavities. Curodont Repair Fluoride Plus is sold in the U.S. and generates the vast majority of revenue, while Curodont Repair is sold in other markets and Curodont Protect is a home-care gel sold in parts of Europe, the UK, and Switzerland. vVARDIS positions Curodont as a first-in-category, non-invasive treatment designed to preserve natural tooth structure and restore enamel crystal density.
The company is competing in a large oral-health market shaped by minimally invasive dentistry, earlier detection through AI-assisted diagnostics, and demand for tooth-preserving treatments. That is a favorable secular backdrop, but it also means vVARDIS is trying to prove that a new category can win against established dental-product and distribution players with deep relationships across practices and channels.
Why They're Going Public
vVARDIS says the IPO will help create a public market for its Class A shares and provide capital for general corporate purposes, working capital, operating expenses, and capital expenditures. The company also says it may use proceeds for acquisitions of complementary businesses, products, services, or technologies.
At the midpoint price of $22.50 per share, vVARDIS estimates net proceeds of about $166.2 million, or about $192.3 million if the underwriters fully exercise the over-allotment option. That capital should give the company more room to expand commercial adoption, support operations, and potentially broaden its product and technology base while it scales beyond an early commercial launch phase.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The top line is growing fast. vVARDIS reported 2025 net revenue of $30.2 million, up 148.5% year over year, with gross profit of $22.4 million and a 74.2% gross margin. For the six months ended June 30, 2026, net revenue reached $28.6 million, up 214.2% year over year, while gross profit rose to $24.7 million and gross margin expanded to 86.4%.
The business is still losing money as it scales. vVARDIS reported a 2025 net loss of $56.5 million and a net loss of $27.8 million for the first half of 2026. The filing also says that since the U.S. launch of Curodont in January 2024, the product had been sold into more than 20,000 dental practices and applied to over 3.5 million teeth by the time of the filing. For the nine months ended September 30, 2026, the company expected net revenue of $47.7 million to $49.2 million, gross profit of $41.1 million to $42.3 million, and net loss of $39.7 million to $41.3 million. It also said recurring buying dental practices reached 11,158 in September 2026.
Risk Factors
The biggest risk is adoption. vVARDIS depends on continued uptake of Curodont by dental practices, and the company’s revenue is concentrated in the U.S. and in a limited number of channels and distributors. If practice-level repeat usage slows or the sales motion proves harder to scale, the growth story can cool quickly.
Regulatory and financing risks also matter. Curodont Repair Fluoride Plus is marketed in the U.S. as an OTC drug product under FDA OTC Monograph M021, and the FDA has not made a product-specific safety or efficacy determination through NDA or ANDA pathways. The prospectus also flags founder share pledges and personal indebtedness, which could create forced-sale pressure, plus lock-up expirations that may weigh on the stock. The company is still loss-making, so the path to durable profitability remains a key watch item.
Comparable Public Companies
The closest public comps are Colgate-Palmolive (CL), Haleon (HLN), Dentsply Sirona (XRAY), Align Technology (ALGN), and Henry Schein (HSIC). Colgate and Haleon are the most direct oral-care consumer peers, while Dentsply Sirona, Align, and Henry Schein give a read on dental products, equipment, and distribution. vVARDIS is much smaller than all of them, but its growth rate is faster than the mature consumer names and its business model is more focused on a single category.
On valuation and trading context, these names generally sit in a mixed-to-mature part of the market rather than a high-flying IPO cohort. The consumer oral-care names tend to trade at steadier, lower-growth multiples, while dental technology and distribution names usually command more cyclical or execution-driven valuations. Recent stock performance across the group has been uneven rather than uniformly hot, which suggests investors are likely to focus on whether vVARDIS can sustain its revenue ramp and convert early adoption into a repeatable commercial model.
Verdict
At $21.00 to $24.00 per share, the IPO gives investors a clearer price on a company with real commercial traction, but also a still-early earnings profile. The setup favors growth-oriented buyers who want exposure to a first-in-category oral-health product with strong revenue momentum, high gross margins, and a large addressable market, while recognizing that the business is not yet profitable and still needs to prove durable adoption beyond the initial launch wave.
What makes this offering notable right now is the combination of a priced IPO, a more than $1 billion prior financing valuation, and a category pitch tied to minimally invasive dentistry and earlier cavity treatment. That is a timely narrative in a market that has shown interest in differentiated healthcare growth stories, but the stock will likely trade on execution: repeat usage, regulatory comfort, and whether the company can keep turning practice adoption into sustained revenue growth after the IPO window opens.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.